Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Merck

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Popular diabetes drug found to contain potential carcinogen

Merck & Co.’s Januvia, a popular diabetes drug, was found to be contaminated with a potential carcinogen.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review

The stock market rally made big moves amid a barrage of earnings and economic reports and another big Fed rate hike.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Merck Dives As Drug-Pricing Bills Undercut Second-Quarter Profit

Merck Dives As Drug-Pricing Bills Undercut Second-Quarter Profit

Merck stock tumbled amid a broad pharma turndown Thursday despite racking up more than $5 billion in sales for cancer drug, Keytruda.

Investors Business Daily

Dow Jones Futures Fall On 'Day 2' After Market Rallies Strongly On Powell Hints Of Slower Fed Rate Hikes

Dow Jones Futures Fall On 'Day 2' After Market Rallies Strongly On Powell Hints Of Slower Fed Rate Hikes

Stocks rallied strongly Wednesday after Fed chief Jerome Powell hinted at slower Fed rate hikes. Watch out for day 2 reactions

Investors Business Daily

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

Investors Business Daily

Dow Jones Futures Rise: Apple Leads Earnings Wave, Fed Rate Hike Looms; What To Do Now

Dow Jones Futures Rise: Apple Leads Earnings Wave, Fed Rate Hike Looms; What To Do Now

The market rally had a strong week despite Friday's losses. Apple leads huge earnings with another big Fed rate hike due.

Investors Business Daily

Dow Jones Stocks Brace For Huge Earnings Week

Dow Jones Stocks Brace For Huge Earnings Week

Chevron and Merck are on deck to report earnings, along with nearly a dozen other Dow Jones stocks. But outlooks are widely mixed.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Falls As ECB Raises Rates; Tesla Surges On Strong Earnings

The Dow Jones Industrial Average fell Thursday, as the European Central Bank hiked interest rates. Tesla stock rallied on strong earnings results.

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab

Pfizer (NYSE: PFE) and its partner, BioNTech (NASDAQ: BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for thei

What's In The Offing For Infosys (INFY) This Earnings Season?

Infosys Limited (NYSE: INFY) is scheduled to report first-quarter fiscal 2023 results on Jul 24. Over the trailing four quarters, the India-based IT services provider's earnings beat the Zacks Consensus Estimate once, met the same on two occasions and missed it once, the average beat being 0.2%.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Investors Business Daily

Dow Jones Falls As Netflix Jumps On Earnings; Tesla Earnings Up Next

The Dow Jones Industrial Average fell Wednesday, as Netflix stock jumped on earnings results. Tesla earnings are due out after the close.

Investors Business Daily

Dow Jones Rallies But IBM Dives On Earnings; Netflix Earnings Due

The Dow Jones Industrial Average rallied Tuesday, but IBM stock dived on earnings. Netflix earnings are due out after the market closes.

Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday

Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share.

Investors Business Daily

Dow Jones Futures: Stock Market Stages Nasty Reversal With Netflix, Tesla Earnings Due

Dow Jones futures were higher after Monday's nasty stock market reversal. Netflix earnings and Tesla earnings are due out this week.

Investors Business Daily

Stock Market Continues Friday's Uptrend; Bank And Airline Stocks Pull Up Dow

The stock market started the week strong after mixed earnings reports from banks, with indexes trading up the last hour but off the highs of the day. The Nasdaq composite was up 1.4% and the S&P 500 gained 0.8%, while the Dow Jones Industrial Average rose 0.6%. The small-cap Russell…

Investors Business Daily

Why Merck's Rumored $40 Billion Seagen Buyout Is On Shaky Ground

Merck is unlikely to finalize the rumored takeover of Seagen before its earnings release, and SGEN stock toppled Monday.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Places

251,500 stories

104,539 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play